10/06/2008 -
Genentech, OSI Lung Cancer Study Falls Short
Genentech and OSI Pharmaceuticals said a late-stage study testing the combination use of Avastin and Tarceva failed to increase overall survival rates.
Source:
TheStreet.com
http://www.thestreet.com/story/10440869/1/genentech-osi-lung-cancer-study-falls-
short.html?puc=_tscrss
|
10/06/2008 -
OSI reports problems with anti-cancer drug
OSI Pharmaceuticals Inc. of Melville and Genentech Inc., its partner in an anti-cancer drug, said Monday a combination of Genentech's Avastin and OSI's Tarceva failed in a study to prolong the lives of patients with the most common form of lung cancer.
Source:
Newsday
http://www.newsday.com/business/ny-bzosi1007,0,1728938.story?track=rss
|
10/07/2008 -
OSI Pharma Gets Bad News, Downgrade
We believe the data will have a negative effect on the share price in the short term and since the price has already achieved our target, we are downgrading the shares from Buy to Hold.
Source:
Zacks.com via Yahoo! Finance
http://biz.yahoo.com/zacks/081007/15116.html?.v=1
|
10/06/2008 -
Genentech And OSI: Avastin-Tarceva Misses An Endpoint
Genentech And OSI: Avastin-Tarceva Misses An Endpoint
Source:
Fox News
http://feeds.foxbusiness.com/~r/foxbusiness/latest/~3/412634106/
|
10/06/2008 -
Genentech and OSI Pharmaceuticals Announce Topline Results from Phase III Study Evaluating the Combination of Avastin ...
Genentech, Inc. (NYSE:DNA) and OSI Pharmaceuticals, Inc. (Nasdaq:OSIP) today announced that a randomized Phase III study (BeTa Lung) evaluating Avastin(R) (bevacizumab) in combination with Tarceva(R) (erlotinib) in patients with advanced non-small cell lung cancer (NSCLC) whose disease had progressed following platinum-based chemotherapy did not meet its primary endpoint of improving overall ...
Source:
Centre Daily Times
http://www.centredaily.com/business/technology/story/884042.html
|
10/06/2008 -
Genentech and OSI Pharmaceuticals Announce Topline Results from Phase III Study Evaluating the Combination of Avastin ...
SOUTH SAN FRANCISCO, Calif. & MELVILLE, N.Y.----Genentech, Inc. and OSI Pharmaceuticals, Inc. today announced that a randomized Phase III study evaluating Avastin® in combination with Tarceva® in patients with advanced non-small cell lung cancer whose disease had progressed following platinum-based chemotherapy did not meet its primary endpoint of improving overall survival compared to Tarceva ...
Source:
Business Wire via Yahoo! Finance
http://biz.yahoo.com/bw/081006/20081005005086.html?.v=1
|
10/08/2008 -
Genentech Has Mixed Results In Cancer Fight
Genentech-Biogen rheumatoid arthritis drug slows progression of lymphocytic leukemia, but trial of lung cancer treatment fails.
Source:
Forbes
http://www.forbes.com/healthcare/2008/10/07/genentech-biogen-closer-markets-equi
ty-cx_lal_1007markets37.html?feed=rss_business_healthcare
|
10/07/2008 -
Problems seen in study of lung cancer drug
MELVILLE, N.Y. ? OSI Pharmaceuticals Inc. and Genentech Inc., partners in an anti-cancer drug, said Monday a combination of Genentech's Avastin and OSI's Tarceva failed in a study to prolong the lives of patients with the most common form of lung cancer.
Source:
The Monterey County Herald
http://www.montereyherald.com/ci_10657844?source=rss
|
10/06/2008 -
Avastin-Tarceva combo fails in lung cancer trial
Genentech Inc. and OSI Pharmaceuticals Inc. said Monday a combination of two cancer drugs missed its primary goal in a clinical trial, failing to improve survival for patients with lung cancer.
Source:
AP via Yahoo! Finance
http://biz.yahoo.com/ap/081006/avastin_tarceva.html?.v=1
|
10/08/2008 -
NFL Insider: More TDs not a mirage; scoring up in '08
So much for the notion those coach-to-defense radio helmets would level the playing field. Scoring is up, turnovers are down and those coaching voices inside designated defenders' helmets can't make the expected difference due to one glaring shortcoming.
Source:
USA Today
http://www.usatoday.com/sports/football/nfl/2008-10-07-nfl-insider_N.htm?csp=34
|
10/06/2008 -
Tarceva, Avastin combo doesn?t increase lung cancer survival
Genentech Inc. and OSI Pharmaceuticals Inc. said a combination of the cancer-fighting drugs Tarceva and Avastin does not show an overall increase in survival rates for lung cancer patients. (DNA) (OSIP)
Source:
BizJournals
http://www.bizjournals.com/sanfrancisco/stories/2008/10/06/daily2.html?ana=from_
rss
|
10/06/2008 -
Genentech shares drop on drug test
Shares of South San Francisco-based Genentech dropped nearly 8 percent after the company announced with OSI Pharmaceuticals that a combination of two cancer drugs, Avastin with Tarceva, missed its primary goal in a clinical trial, failing to improve survival for patients with late-stage lung cancer.
Source:
Contra Costa Times
http://www.contracostatimes.com/ci_10651015?source=rss
|
10/06/2008 -
Topline Results From Phase III Study Evaluating The Combination Of Avastin And Tarceva As 2nd-Line Treatment For ...
Genentech, Inc. (NYSE:DNA) and OSI Pharmaceuticals, Inc.
Source:
Medical News Today
http://www.medicalnewstoday.com/articles/124347.php
|
10/08/2008 -
GIANTS NEEDN'T WORRY ABOUT LAID-BACK RECEIVER
PLAXICO Burress isn't taking the Giants anywhere except for another ride into the playoffs. He's a terrific player who not one teammate emulates when it comes to punctuality or the art of the phone call. No one has to worry that the return of...
Source:
New York Post
http://www.nypost.com/seven/10082008/sports/giants/giants_neednt_worry_about_lai
d_back_rece_132577.htm
|
10/07/2008 -
CBL & Associates, Starrett LS and Morgans Hotel Group among 52-week lows
CBL & Associates REIT , Starrett LS Co. and Morgans Hotel Group Co. are among the new 52-week lows in Tuesday's trading among companies with market...
Source:
SmallCapInvestor.com via Yahoo! Finance
http://biz.yahoo.com/smallcapinvestor/081007/11311.html?.v=1
|
